HI-PEITHO Analysis Studies Predictors of Major Bleeding in Acute Intermediate-Risk PE

October 16, 2026—A post hoc analysis of the randomized HI-PEITHO study examined potential predictors of major bleeding in patients with acute intermediate-risk pulmonary embolism (PE) treated with ultrasound-facilitated catheter-directed thrombolysis (USCDT) using the Ekos endovascular system (Boston Scientific Corporation) plus anticoagulation (AC) or anticoagulation (AC) alone.

Translumina Initiates SPARX RCT to Advance Evidence for DCBs in Complex Coronary Disease

October 15, 2026—Translumina Therapeutics Private Limited, India, announced initiation of the SPARX global randomized controlled trial (RCT), which is sponsored by the company.

Enrollment Completed in BIOMAG-LL Study of Teleflex Freesolve RMS in Longer Lengths

October 15, 2026—Teleflex Incorporated announced the successful completion of patient enrollment in the BIOMAG-LL clinical study.

Vantis Vascular’s 6-F CrossFast System Receives FDA Clearance 

October 14, 2026—Vantis Vascular announced FDA 510(k) clearance for a new 6-F model of its CrossFast integrated microcatheter advanced delivery system.

Thrombolex Device for Mechanically Channeled Thrombolysis Evaluated in RAPID-PE

October 13, 2026—Thrombolex, Inc., announced interim results from the first 150 patients enrolled in its RAPID-PE postmarket study, a prospective, multicenter, single-arm study evaluating on-the-table mechanically channeled thrombolysis using the Thrombolex device for acute intermediate-risk pulmonary embolism (PE).

FDA Clears E2 Hēlo Thrombectomy System and Integrated Blood Return System

October 13, 2026—Endovascular Engineering, Inc. (E2), a developer of technology for venous thromboembolism, announced FDA 510(k) clearance for both the Hēlo thrombectomy system and Hēlo Return, a blood return system.

Recross Cardio’s Global PROTEA-PFO Clinical Program Marks Enrollment Milestone

October 12, 2026—Recross Cardio Inc., a structural heart company developing membrane-based technologies for septal management, announced that enrollment has reached 25 patients in the PROTEA-PFO clinical program evaluating the company’s patent foramen ovale (PFO) sealing system.

Boston Scientific Appoints Joseph M. Fitzgerald as COO and Creates Three-Segment Business Structure

October 12, 2026—Boston Scientific Corporation announced the appointment of Joseph M. Fitzgerald to Executive Vice President and Chief Operating Officer (COO), effective January 1, 2027. He will oversee the company’s global operations, business units, and regions. Fitzgerald currently serves as Executive Vice President and Group President, Cardiovascular, Boston Scientific.

SMT’s Supraflex Cruz Receives EU MDR Certification

October 9, 2026—Sahajanand Medical Technologies Limited (SMT), an India-based global manufacturer of cardiovascular medical devices, announced that it has received certification under the European Union Medical Device Regulation (EU MDR 2017/745) for Supraflex Cruz and its product family.

AngioDynamics Appoints Eric Honroth as President and Chief Executive Officer

October 9, 2026—AngioDynamics, Inc. announced the appointment of Eric Honroth as President, Chief Executive Officer, and a member of the company’s board of directors.